Chan Jonathan C H, Cowley Emily, Chan Michael
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.
J Cardiovasc Dev Dis. 2023 Mar 9;10(3):114. doi: 10.3390/jcdd10030114.
Heart failure (HF) is a complex clinical syndrome involving structural and/or functional abnormalities of the heart. Heart failure is often classified based on left ventricular ejection fraction, which serves as a predictor of mortality. The majority of the data supporting disease-modifying pharmacological therapies are from patients with reduced ejection fraction (less than 40%). However, with the recent results from the sodium glucose cotransporter-2 inhibitor trials, there is renewed interest in identifying potential beneficial pharmacological therapies. This review focuses on and includes pharmacological HF therapies across the spectrum of ejection fraction, providing an overview of the novel trials. We also examined the effects of the treatments on mortality, hospitalization, functional status, and biomarker levels to further investigate the interplay between ejection fraction and HF.
心力衰竭（HF）是一种涉及心脏结构和/或功能异常的复杂临床综合征。心力衰竭通常根据左心室射血分数进行分类，左心室射血分数可作为死亡率的预测指标。支持改善病情的药物治疗的大多数数据来自射血分数降低（小于40%）的患者。然而，随着钠-葡萄糖协同转运蛋白2抑制剂试验的最新结果，人们对确定潜在有益的药物治疗重新产生了兴趣。本综述重点关注并涵盖了整个射血分数范围内的心力衰竭药物治疗，概述了新的试验。我们还研究了这些治疗对死亡率、住院率、功能状态和生物标志物水平的影响，以进一步探讨射血分数与心力衰竭之间的相互作用。
